Jubilant Pharmova Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| JUBLPHARMA.NS | TEVA | MOREPENLAB.NS | GLENMARK.NS | GRANULES.BO | AJANTPHARM.NS | |
|---|---|---|---|---|---|---|
| Market cap | 148.63B | 45.96B | 67.69B | 611.47B | 192.86B | 410.35B |
| P/E (TTM) | 42.3 | 66.8 | 48.3 | 34.0 | 35.3 | 36.2 |
| Forward P/E | 18.6 | 12.8 | — | 22.3 | 26.5 | 28.2 |
| Price/book | 2.1 | 5.9 | 5.6 | 5.8 | 4.8 | 9.1 |
| Dividend yield | 0.54% | — | 0.17% | 0.11% | 0.26% | 1.96% |
| 1-year change | −16.66% | +112.19% | +140.93% | +20.88% | +0.63% | +35.46% |
| Today | +0.65% | −1.99% | +4.99% | −1.45% | −2.70% | +0.41% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All JUBLPHARMA.NS news ›Quant MF sells Jubilant Pharmova stake for over ₹100 crore; stock falls over 2%
Quant Mutual Fund has sold nearly 1 per cent stake in Jubilant Pharmova for over ₹100 crore through an open market transaction, according to NSE data. Quant Mutual Fund (Quant MF) offloaded 11 lakh shares, representing a 0.69 per cent…
Jubilant Pharmova approves ₹800 crore NCD issue through private placement
Jubilant Pharmova has approved an NCD issue of up to ₹800 crore through private placement, with the debentures proposed to be listed on the BSE. Jubilant Pharmova Ltd on Monday said its Board of Directors has approved the issuance of…
Jubilant Pharmova Board Approves Rs 800 Cr NCD Issue
Jubilant Pharmova's board approved issuing non-convertible debentures (NCDs) worth Rs 800 crore via private placement, with shareholder approval sought for up to Rs 2,500 crore. Key PointsJubilant Pharmovas board approved issuing…
Jubilant Pharmova Board Approves Issuance of Non-Convertible Debentures up to ₹800 Crore
EquityBulls Jubilant Pharmova Board Approves Issuance of Non-Convertible Debentures up to ₹800 Crore Jubilant Pharmova Limited has announced that its Board of Directors, at its meeting held on October 12, 2026, approved the issuance of…
Jubilant Pharmova Board Approves ₹800 Crore NCD Issue And Seeks ₹2,500 Crore Debt Approval
Jubilant Pharmova plans to raise up to ₹800 crore through private placement of NCDs and seeks member approval for a broader ₹2,500 crore borrowing umbrella via debt securities over the next year to fund business objectives and optimize its…
Jubilant Pharmova to issue non-convertible debentures worth ₹800 crore
Jubilant Pharmova Limited has announced its plan to issue non-convertible debentures (NCDs) aggregating up to ₹800 crore. The announcement was made following the approval from the company's Board of Directors during their meeting held on…
How Can Jubilant Pharmova Be a “Contra Bet” to the US Pharma Tariff?
The article outlines the industry headwind and the company being a contra bet to the headwind, which is an integrated global pharmaceuticals company having three business segments which are pharmaceuticals, contract research and…
Sensex, Nifty Today LIVE: NSE Stock Market Updates, Oct 12, 2026: Jubilant Pharmova plans ₹800 crore NCD issuance | Jubilant Pharmova issuing ₹800 crore debentures
Jubilant Pharmova Limited plans to issue Non-Convertible Debentures worth up to ₹800 crore on a private placement basis. Jubilant Pharmova to issue NCDs worth ₹800 crore on private placement basis. Mastek and CORT win the ISG Paragon…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
businessupturn.com6
-
sahi.com2
-
thehindubusinessline.com2
-
tradebrains.in2
-
business-standard.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 18 articles, not a forecast.